Detalhe da pesquisa
1.
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.
N Engl J Med
; 388(19): 1755-1766, 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163622
2.
Use of omalizumab for management of idiopathic anaphylaxis: A systematic review and retrospective case series.
Ann Allergy Asthma Immunol
; 127(4): 481-487, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34175498
3.
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results.
J Allergy Clin Immunol
; 146(4): 863-874, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32659313
4.
Current management and use of oral immunotherapy in the United States for patients with peanut allergy.
Allergy Asthma Proc
; 40(4): 214-220, 2019 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31122310
5.
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial.
JAMA
; 321(10): 946-955, 2019 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30794314
6.
Identification of mast cell progenitor cells in the airways of individuals with allergic asthma.
Allergy
; 78(2): 547-549, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36038252
7.
From clinical observations and molecular dissection to novel therapeutic strategies for primary immunodeficiency disorders.
Am J Med Genet A
; 176(4): 784-803, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28941161
8.
Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab.
Clin Exp Allergy
; 51(12): 1648-1652, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34519110
9.
Extracellular vesicle microRNAs as predictors of response to omalizumab in chronic spontaneous urticaria.
Allergy
; 76(4): 1274-1277, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33314187
10.
Approach to the evaluation of adverse antibiotic reactions in patients with cystic fibrosis.
Ann Allergy Asthma Immunol
; 117(4): 378-381, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27590641
11.
Clinical response to omalizumab in patients with hereditary α-tryptasemia.
Ann Allergy Asthma Immunol
; 124(1): 99-100.e1, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31605754
12.
Omalizumab for chronic urticaria in children younger than 12 years.
Ann Allergy Asthma Immunol
; 123(2): 208-210.e2, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31082483
13.
Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow's Milk Allergy: A Randomized Clinical Trial.
JAMA Pediatr
; 178(4): 345-353, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38407859
14.
FDA-approved peanut allergy treatment: The first wave is about to crest.
Ann Allergy Asthma Immunol
; 121(2): 145-149, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29909055
15.
Eosinophilic esophagitis and symptoms possibly related to eosinophilic esophagitis in oral immunotherapy.
Ann Allergy Asthma Immunol
; 120(3): 237-240.e4, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29397272
16.
Attenuation of low dose methylmercury and glutamate induced-cytotoxicity and tau phosphorylation by an N-methyl-D-aspartate antagonist in human neuroblastoma (SHSY5Y) cells.
Environ Toxicol
; 28(12): 700-6, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21976409
17.
Low-dose methylmercury-induced oxidative stress, cytotoxicity, and tau-hyperphosphorylation in human neuroblastoma (SH-SY5Y) cells.
Environ Toxicol
; 27(9): 549-55, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21254321
18.
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results.
J Allergy Clin Immunol Pract
; 10(7): 1864-1873.e10, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34848381
19.
Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study.
J Allergy Clin Immunol Pract
; 9(5): 1879-1889.e13, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33359589
20.
Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy.
JCI Insight
; 4(22)2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31723064